• 1
    Cantor WJ, Fitchett D, Borgundvaag B Ducas J, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Me 2009;360:27052718.
  • 2
    Olszowska M, Tracz W, Kostkiewicz M, Podolec P. Predictive factors of myocardial reperfusion in patients with anterior wall acute myocardial infarction. Cardiol J 2008;15:5762.
  • 3
    Zhao JL, Yang YJ, Pei WD, Sun YH, Chen JL. The effect of statins on the no-reflow phenomenon: An observational study in patients with hyperglycemia before primary angioplasty. Am J Cardiovasc Drugs 2009;9:8189.
  • 4
    Vrints CJ. Pathophysiology of the no-reflow phenomenon. Acute Card Care 2009;11:6976.
  • 5
    Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag 2009;5:2129.
  • 6
    Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol 2008;13:121128.
  • 7
    Muller O, Windecker S, Cuisset T, et al. Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations. EuroIntervention 2008;4:181183.
  • 8
    Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008;72:950957.
  • 9
    Fischell TA. Pharmaceutical interventions for the management of no-reflow. J Invasive Cardiol 2008;20:374379.
  • 10
    Lee KW, Norell MS. Management of ‘no-reflow’ complicating reperfusion therapy. Acute Card Care 2008;10:514.
  • 11
    Bommer WJ. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 2. Prev Cardiol 2008;11:215222.
  • 12
    Matsuoka H. Large clinical trials of ARB in Japan and its reflection to new guidelines. Nippon Rinsho 2009;67:6974.
  • 13
    Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Euro Heart J 2008;29:29092945.
  • 14
    Kim-Mitsuyama S. Pharmacological characteristics of ARB and potential strategy to develop novel ARB. Nippon Rinsho 2009;67:812818.
  • 15
    Ferrario C. Effect of angiotensin receptor blockade on endothelial function: Focus on olmesartan medoxomil. Vasc Health Risk Manag 2009;5:301314.
  • 16
    Meneveau N, Séronde MF, Descotes-Genon V Dutheil J, et al. Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: A matched comparison in acute myocardial infarction patients. Clin Res Cardiol 2009;98:257264.